Bio-Techne Co. (NASDAQ:TECH – Get Free Report) declared a quarterly dividend on Saturday, August 17th, RTT News reports. Investors of record on Monday, August 19th will be paid a dividend of 0.08 per share by the biotechnology company on Friday, August 30th. This represents a $0.32 annualized dividend and a dividend yield of 0.43%. The ex-dividend date is Monday, August 19th.
Bio-Techne has a dividend payout ratio of 16.9% indicating that its dividend is sufficiently covered by earnings. Equities research analysts expect Bio-Techne to earn $2.12 per share next year, which means the company should continue to be able to cover its $0.32 annual dividend with an expected future payout ratio of 15.1%.
Bio-Techne Trading Down 0.5 %
Shares of TECH opened at $74.52 on Friday. Bio-Techne has a fifty-two week low of $51.79 and a fifty-two week high of $85.57. The company has a market capitalization of $11.74 billion, a PE ratio of 59.14, a price-to-earnings-growth ratio of 4.69 and a beta of 1.29. The stock has a fifty day moving average of $75.37 and a two-hundred day moving average of $73.46. The company has a debt-to-equity ratio of 0.15, a quick ratio of 2.75 and a current ratio of 3.87.
Wall Street Analyst Weigh In
A number of equities research analysts recently issued reports on TECH shares. Royal Bank of Canada lowered their target price on shares of Bio-Techne from $72.00 to $70.00 and set a “sector perform” rating for the company in a report on Thursday, August 8th. Benchmark reissued a “buy” rating and set a $95.00 price objective on shares of Bio-Techne in a research note on Tuesday, August 13th. Citigroup lowered Bio-Techne from a “buy” rating to a “neutral” rating and set a $85.00 target price on the stock. in a research report on Wednesday, May 22nd. Finally, Robert W. Baird boosted their price target on Bio-Techne from $81.00 to $82.00 and gave the company an “outperform” rating in a research report on Thursday, August 8th. Four analysts have rated the stock with a hold rating and eight have given a buy rating to the company. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $80.60.
View Our Latest Analysis on TECH
About Bio-Techne
Bio-Techne Corporation, together with its subsidiaries, develops, manufactures, and sells life science reagents, instruments, and services for the research and clinical diagnostic markets in the United States, the United Kingdom, rest of Europe, Middle East, and Africa, Greater China, rest of Asia-Pacific, and internationally.
Further Reading
- Five stocks we like better than Bio-Techne
- Uptrend Stocks Explained: Learn How to Trade Using Uptrends
- This Small Cap Wealth Management Stock Could Provide Big Returns
- Retail Stocks Investing, Explained
- Bumble’s Valuation Hits an All-Time Low, Can Its Fortunes Change?
- Where to Find Earnings Call Transcripts
- MarketBeat Week in Review – 8/12 – 8/16
Receive News & Ratings for Bio-Techne Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bio-Techne and related companies with MarketBeat.com's FREE daily email newsletter.